{"gene":"FKBP1A","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":1993,"finding":"Crystal structures of human FKBP12 complexed with FK506 and rapamycin revealed a novel fold (five-stranded beta-sheet wrapping a short alpha-helix) with both ligands binding in a cavity defined by the beta-sheet, alpha-helix and three loops via hydrogen bonds and an unusual carbonyl binding pocket. The structures suggest how peptidyl-prolyl isomerase (PPIase) catalytic activity could operate.","method":"X-ray crystallography (high-resolution structures of FKBP12-FK506 and FKBP12-rapamycin complexes)","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — atomic-resolution crystal structures with functional validation of ligand-binding mode, foundational structural paper","pmids":["7678431"],"is_preprint":false},{"year":1994,"finding":"FKBP12 binds the mammalian TOR homolog RAFT1 (mTOR) in a rapamycin-dependent fashion; purified FKBP12-rapamycin complex specifically precipitates the 289-kDa RAFT1/mTOR protein, identifying it as the direct cellular target of the FKBP12-rapamycin complex.","method":"Affinity purification (FKBP12-rapamycin affinity matrix), peptide sequencing, cDNA cloning","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — replicated independently in multiple labs (PMID 7518356, 7822316, 7539137), biochemical pulldown with sequence confirmation","pmids":["7518356","7822316"],"is_preprint":false},{"year":1995,"finding":"An 11-kDa FKBP12-rapamycin-binding (FRB) domain within FRAP/mTOR (residues 2025–2114) was identified as the minimal binding domain for the FKBP12-rapamycin complex. Mutagenesis at Ser2035 showed that most substitutions abolish binding, whereas Ser2035Ala retains binding, suggesting steric rather than phosphorylation-based regulation at this site.","method":"In vitro transcription/translation, proteolysis mapping, site-directed mutagenesis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with mutagenesis defining the minimal binding domain","pmids":["7539137"],"is_preprint":false},{"year":1996,"finding":"Crystal structure of the ternary FKBP12–rapamycin–FRB(FRAP) complex at 2.7 Å revealed that rapamycin simultaneously occupies two different hydrophobic binding pockets on FKBP12 and FRB, mediating protein dimerization with extensive rapamycin-protein interactions but fewer direct protein-protein contacts.","method":"X-ray crystallography (2.7 Å resolution ternary complex)","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 / Strong — atomic-resolution ternary complex structure, refined further at 2.2 Å (PMID 10089303)","pmids":["8662507","10089303"],"is_preprint":false},{"year":1995,"finding":"Crystal structure of human FKBP12-FK506 bound to calcineurin (CaN) at 3.5 Å resolution revealed the FKBP12-FK506 complex displaces the calcineurin auto-inhibitory element from the active site. Surface residues Asp-37, Arg-42, and His-87 of FKBP12 (identified by mutagenesis) directly participate in calcineurin complex formation; R42K/H87V double mutant reduced calcineurin affinity ~600-fold without affecting PPIase activity or FK506 binding.","method":"X-ray crystallography, site-directed mutagenesis, calcineurin inhibition assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure combined with mutagenesis defining contact residues, two independent papers","pmids":["8524402","1379588"],"is_preprint":false},{"year":1994,"finding":"FKBP12 specifically interacts with type I receptors of the TGF-beta family (identified by yeast two-hybrid screen); deletion and point mutation studies confirmed specificity, and excess FK506 competed with type I receptors for FKBP12 binding, suggesting shared/overlapping binding sites.","method":"Yeast two-hybrid screen, co-immunoprecipitation, competition binding with FK506","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — replicated and extended by multiple independent labs (PMID 8756725, 9233797)","pmids":["7518616"],"is_preprint":false},{"year":1996,"finding":"FKBP12 acts as a common inhibitor of TGF-beta family type I receptors: it binds to ligand-free type I receptor and is released upon ligand-induced, type II receptor-mediated phosphorylation. Two FKBP12 point mutations (G89P, I90K) abolish its inhibitory activity; overexpression of myristylated FKBP12 specifically inhibits two TGF-beta-activated pathways.","method":"Co-immunoprecipitation, overexpression with point mutations, cell-based inhibition assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (Co-IP, mutagenesis, overexpression phenotype), replicated across labs","pmids":["8756725"],"is_preprint":false},{"year":1997,"finding":"FKBP12 binds TbetaR-I via the rapamycin/Leu-Pro binding pocket of FKBP12 and a Leu-Pro sequence adjacent to the activating phosphorylation sites of TbetaR-I. FKBP12 does not block TbetaR-I/TbetaR-II association but inhibits TbetaR-I phosphorylation by TbetaR-II; rapamycin reverses this inhibition by blocking FKBP12 binding to TbetaR-I.","method":"Mutagenesis of FKBP12 and TbetaR-I binding sites, kinase phosphorylation assays, rapamycin competition","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — mechanistic dissection using mutagenesis at both binding partners plus in vitro kinase assays","pmids":["9233797"],"is_preprint":false},{"year":1997,"finding":"FKBP12 binds the inositol 1,4,5-trisphosphate receptor (IP3R) at residues Leu1400-Pro1401 (a leucyl-prolyl dipeptide epitope resembling FK506) and this interaction enables FKBP12 to anchor calcineurin to the IP3R, presumably to modulate the receptor's phosphorylation status.","method":"Mutagenesis mapping, co-immunoprecipitation, peptide competition assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical mapping with mutagenesis, single lab but multiple methods","pmids":["9346894"],"is_preprint":false},{"year":1998,"finding":"FKBP12-deficient mice develop severe dilated cardiomyopathy, ventricular septal defects resembling noncompaction of left ventricular myocardium, and altered calcium release activity of both skeletal (RyR1) and cardiac (RyR2) ryanodine receptors; FKBP12 is dispensable for TGF-beta-mediated signaling in vivo.","method":"Conditional knockout mice (ES cell technology), physiological Ca2+ release measurements, cardiac phenotyping","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function with defined cardiac and ryanodine receptor phenotypes, replicated by other groups","pmids":["9461216"],"is_preprint":false},{"year":1995,"finding":"FKBP12 physically and stoichiometrically binds RyR1 in skeletal muscle (4 FKBP12 per tetrameric RyR1); dissociation of FKBP12 from the RyR complex by FK-590 or rapamycin increases RyR1 open probability and Ca2+ leak. PPIase-deficient FKBP12 mutants can bind and modulate RyR1 normally, indicating RyR1 modulation is independent of PPIase activity.","method":"Exchange binding assays, Ca2+ flux measurements, site-directed mutagenesis of FKBP12 PPIase active site","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro reconstitution with mutagenesis, functional flux assays, replicated across multiple labs","pmids":["7531689"],"is_preprint":false},{"year":1996,"finding":"The cardiac ryanodine receptor (RyR2) selectively binds FKBP12.6 but not FKBP12 from the cardiac sarcoplasmic reticulum, whereas skeletal RyR1 binds both isoforms. This differential selectivity explains the isoform specificity of RyR-FKBP complexes in different muscle types.","method":"35S-labeled FKBP12 and FKBP12.6 binding assays on FKBP-stripped cardiac and skeletal SR vesicles","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct binding experiments with radiolabeled probes on native membranes, replicated","pmids":["8702774"],"is_preprint":false},{"year":2001,"finding":"Val2461 in RyR1 is a critical residue required for FKBP12 binding; substitution with Gly, Glu, or Ile prevents FKBP12 binding and results in RyR1 channels with increased gating frequency; normal channel function can be restored by adding FKBP12.6 to V2461I mutant channels.","method":"Site-directed mutagenesis of RyR1, single-channel electrophysiology, FKBP12 binding assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis with functional rescue and single-channel readout","pmids":["11279144"],"is_preprint":false},{"year":2001,"finding":"FKBP12 deficiency causes G1 cell cycle arrest via TGF-beta receptor over-signaling, leading to marked upregulation of p21(WAF1/CIP1) through the p38 MAP kinase pathway (not ERK or SMAD); dominant-negative TGF-beta receptor rescues the arrest.","method":"FKBP12-/- mouse cells, transfection rescue, dominant-negative TGF-beta receptor, p38 inhibitor, p21 western blotting","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function with multiple orthogonal epistasis experiments defining pathway","pmids":["11226255"],"is_preprint":false},{"year":2003,"finding":"FKBP12-deficient mice exhibit exercise-induced cardiac arrhythmias; exercise-induced PKA phosphorylation of RyR2 partially dissociates FKBP12.6 from RyR2, increasing intracellular Ca2+ release; CPVT-associated RyR2 mutations reduce FKBP12.6 affinity and increase channel activity under exercise-simulating conditions.","method":"FKBP12.6 knockout mice, single-channel electrophysiology, in vivo exercise challenge, co-immunoprecipitation","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with in vivo cardiac phenotype and mechanistic biochemistry","pmids":["12837242"],"is_preprint":false},{"year":2004,"finding":"PKA phosphorylation at Ser2808 of RyR2 does NOT dissociate FKBP12.6 from RyR2; FKBP12.6 binds both the phosphorylated and nonphosphorylated forms; the S2808D phosphomimetic mutant retains FKBP12.6 binding. Complete PKA phosphorylation at Ser2808 disrupts neither recombinant nor native FKBP12.6-RyR2 complex.","method":"Site-specific phospho-antibodies, co-immunoprecipitation with recombinant and native RyR2, exogenous PKA phosphorylation","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — negative result established with multiple rigorous methods and site-specific tools; contradicts earlier claims","pmids":["14715536"],"is_preprint":false},{"year":2005,"finding":"Cryo-EM difference mapping at 16 Å resolution determined the 3D position and unique orientation of FKBP12 bound to RyR1; the FK506-binding site of FKBP12 faces toward RyR1, explaining how FK506 causes FKBP12 dissociation; Gln3 of FKBP12 was identified as directly participating in the RyR1 interaction.","method":"Cryo-electron microscopy, single-particle image processing, atomic model fitting","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — cryo-EM structural determination with atomic model fitting, single lab","pmids":["16405911"],"is_preprint":false},{"year":2003,"finding":"FKBP12 binding to RyR1 enhances the gain of skeletal muscle excitation-contraction (EC) coupling; RyR1 mutations disrupting FKBP12 binding (V2461G, V2461I) reduce voltage-gated Ca2+ release ~50%; co-expression of FKBP12.6 restores normal EC coupling in V2461I myotubes. FKBP12 binding does not affect retrograde coupling.","method":"Expression of RyR1 mutants in dyspedic myotubes (RyR1-KO), voltage-clamp fluorometry, caffeine-induced Ca2+ release","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — rescue experiment with mutagenesis in null background, multiple functional readouts","pmids":["12704193"],"is_preprint":false},{"year":2008,"finding":"Brain-specific FKBP12 knockout mice show increased basal mTOR phosphorylation, enhanced mTOR-Raptor interactions, increased p70 S6K phosphorylation, enhanced LTP, and enhanced contextual fear memory with autistic/OCD-like perseveration; the LTP enhancement is rapamycin-resistant but anisomycin-sensitive, implicating altered translational control.","method":"Conditional knockout mice (brain-specific), co-immunoprecipitation of mTOR-Raptor, electrophysiology (LTP), behavioral assays","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with multiple orthogonal biochemical and functional readouts","pmids":["19081378"],"is_preprint":false},{"year":2013,"finding":"Endothelial cell-specific (not cardiomyocyte-specific) ablation of Fkbp1a recapitulates ventricular hypertrabeculation and noncompaction; Fkbp1a is a negative modulator of activated Notch1 (N1ICD) in endocardial cells; N1ICD is upregulated upon Fkbp1a ablation and direct inhibition of Notch signaling reduces hypertrabeculation.","method":"Conditional knockout mice (endothelial vs cardiomyocyte-specific Cre), in vivo and in vitro Notch1 activity assays, N1ICD stability measurements","journal":"Development","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific KO with epistasis (Notch inhibition rescue), multiple orthogonal methods","pmids":["23571217"],"is_preprint":false},{"year":2006,"finding":"FKBP12 acts as an adaptor for the Smad7-Smurf1 complex on the activin type I receptor (ALK4): after initial ligand-induced dissociation, FKBP12 re-associates with ALK4 and recruits Smad7. FK506, which dissociates FKBP12 from the receptor, decreases Smad7-Smurf1 interaction and inhibits Smurf1-mediated ubiquitination of the type I receptor.","method":"Co-immunoprecipitation, ubiquitination assays, FK506 competition","journal":"Journal of molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and ubiquitination assays, single lab","pmids":["16720724"],"is_preprint":false},{"year":2017,"finding":"FKBP12 preferentially binds the BMP type I receptor ALK2 and inhibits hepcidin expression; sequestration of FKBP12 by rapamycin or tacrolimus activates BMP-SMAD signaling and increases hepcidin both in vitro and in vivo; ALK2 mutants defective in FKBP12 binding show ligand-independent hepcidin activation and gain responsiveness to the non-canonical ligand Activin A.","method":"Pharmacologic (rapamycin/tacrolimus treatment), genetic (ALK2 binding-deficient mutants), in vitro and murine hepatocyte models, SMAD signaling assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal approaches (pharmacologic + genetic) with in vivo validation","pmids":["28864813"],"is_preprint":false},{"year":2017,"finding":"FKBP12 endogenously regulates calcineurin activity toward a specific subset of substrates and promotes dephosphorylation of proteins contributing to alpha-synuclein toxicity; partial pharmacological disruption of FKBP12-calcineurin interaction with low-dose tacrolimus protects against alpha-synuclein pathology in a rat PD model.","method":"Quantitative phosphoproteomics, genetic manipulation of FKBP12-calcineurin interaction, in vivo rat PD model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — quantitative phosphoproteomics with in vivo validation, multiple orthogonal methods","pmids":["29229832"],"is_preprint":false},{"year":2019,"finding":"FKBP12 is essential for necroptosis: it is required for RIPK1 and RIPK3 expression and spontaneous phosphorylation, necrosome formation, and RIPK1-RIPK3-MLKL signaling pathway activation in response to TNF receptor 1 ligation; FKBP12 may target RIPK1 and RIPK3 directly.","method":"siRNA/shRNA knockdown, in vitro and in vivo TNF-induced necroptosis assays, western blot for necrosome components","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined molecular phenotype, single lab, mechanistic details incompletely resolved from abstract","pmids":["31028177"],"is_preprint":false},{"year":2016,"finding":"FKBP12 interacts with MDM2 and induces MDM2 degradation via disruption of the MDM2/MDM4 interaction and induction of MDM2 self-ubiquitination; FKBP12 preferentially degrades cytoplasmic MDM2; DNA-damage-induced nuclear MDM2 translocates to the cytoplasm where it is targeted by FKBP12, leading to constitutive p53 activation and sensitization of cancer cells to apoptosis.","method":"Co-immunoprecipitation, ubiquitination assays, subcellular fractionation, siRNA knockdown, apoptosis assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ubiquitination assay plus functional apoptosis readout, single lab","pmids":["27617579"],"is_preprint":false},{"year":2002,"finding":"FKBP12 is the only FKBP family member required for FK506-mediated T-cell growth inhibition; FK506-induced T-cell suppression is abolished in FKBP12-deficient cells but not FKBP12.6-deficient cells.","method":"FKBP12-/- and FKBP12.6-/- mouse T cells, T-cell growth inhibition assay with FK506","journal":"Transplantation","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct genetic comparison of isoform-specific KO cells with functional readout","pmids":["12085010"],"is_preprint":false},{"year":2012,"finding":"FKBP12 (not FKBP12.6) is a high-affinity activator of cardiac RyR2, sensitizing the channel to cytosolic Ca2+; FKBP12.6 has very low efficacy on RyR2 but antagonizes FKBP12 effects. Physiological concentrations of FKBP12 (3 µM) increase Ca2+ wave frequency and decrease SR Ca2+ content in cardiac cells.","method":"Single-channel bilayer electrophysiology, Ca2+ wave imaging in permeabilized cardiac cells, mathematical modeling","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — single-channel recordings with physiological concentrations plus cell imaging, single lab","pmids":["22363773"],"is_preprint":false},{"year":2011,"finding":"FKBP12 inhibits EGF-induced EGFR autophosphorylation at all internal phosphorylation sites by targeting the EGFR kinase domain; altering intracellular FKBP12 levels changes EGFR autophosphorylation level.","method":"In vitro kinase assays, siRNA knockdown/overexpression with EGFR phosphorylation readout","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro kinase inhibition plus cellular gain/loss-of-function, single lab","pmids":["22103444"],"is_preprint":false},{"year":2005,"finding":"RyR1 S-nitrosylation (but not S-glutathionylation) specifically increases the Kd of FKBP12 binding to RyR1 by four- to five-fold, reducing FKBP12 association with the channel.","method":"Radiolabeled [35S]FKBP12 binding assays, redox modification of native RyR1 in triads","journal":"Antioxidants & redox signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding assay with specific redox modifications, single lab","pmids":["15998242"],"is_preprint":false},{"year":2015,"finding":"Crystal structures of RyR SPRY1 domain at 1.2–1.5 Å combined with FRET studies and molecular dynamics/mutagenesis identified a hydrophobic cluster within SPRY1 as crucial for FKBP binding; the RyR1 disease mutation N760D disrupts FKBP binding by interfering with SPRY1 folding.","method":"X-ray crystallography, FRET, cryo-EM docking, site-directed mutagenesis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures combined with mutagenesis and FRET, multiple orthogonal methods","pmids":["26245150"],"is_preprint":false},{"year":2017,"finding":"Cryo-EM structure of RyR2-FKBP12.6 complex at 11.8 Å revealed that FKBP12.6 binding rigidifies the HD2 (helical domain 2/Clamp) domain of RyR2, stabilizing the closed state; two RyR2 conformations were identified corresponding to different phosphorylation states of the P2 domain, suggesting phosphorylation lowers the energy barrier to channel opening.","method":"Cryo-electron microscopy (11.8 Å resolution), atomic model building","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1 / Moderate — cryo-EM structure with atomic modeling, single lab","pmids":["28536302"],"is_preprint":false},{"year":2021,"finding":"FKBP12 is expressed along the actin cytoskeleton of podocytes and associates with filamentous actin (F-actin), 14-3-3, and synaptopodin; FKBP12 silencing reduces 14-3-3 expression, F-actin staining, and process formation; tacrolimus restores FKBP12 at F-actin and enhances FKBP12-synaptopodin interaction, ameliorating podocyte injury.","method":"RNA silencing, confocal immunofluorescence, co-immunoprecipitation, podocyte morphology assays","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function plus protein interaction studies with functional readout, single lab","pmids":["34662453"],"is_preprint":false},{"year":2018,"finding":"FKBP12 over-expression suppresses basal BMP signaling of thirteen of fourteen FOP/DIPG-associated gain-of-function ALK2 mutants; the PF197-8L (L197) mutant uniquely resists FKBP12 suppression because modeled steric clash between ALK2-L197 and FKBP12-D36 disrupts binding; co-expression of BMP type II receptors or ligand stimulation relieves FKBP12 suppression by disrupting the mutant ALK2–FKBP12 interaction.","method":"Overexpression studies, signaling assays (BMP-SMAD), molecular modeling of binding interface","journal":"Bone","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic mutagenesis panel with functional signaling readout, supported by structural modeling, single lab","pmids":["29551750"],"is_preprint":false},{"year":2025,"finding":"Fully synthetic FKBP12-mTOR molecular glues were discovered from a FKBP-focused ligand library; crystal structure of the ternary complex revealed the compounds target a similar FRB domain surface as rapamycin but with a radically different interaction pattern; structure-guided optimization yielded compounds inducing FKBP12-FRB complex formation in cells.","method":"Biochemical screening, X-ray crystallography of ternary complex, structure-activity relationship optimization, cell-based FKBP12-FRB dimerization assay","journal":"Chemical science","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure of ternary complex plus cell-based validation, single lab but multiple orthogonal methods","pmids":["39916884"],"is_preprint":false},{"year":1995,"finding":"TOR1 and mTOR (as well as TOR2) directly interact with FKBP12-rapamycin complex; a conserved serine residue (Ser1972 in TOR1, corresponding to Ser2035 in mTOR) is required for this interaction; mutations at this serine confer rapamycin resistance by preventing FKBP12-rapamycin binding; FKBP12 prolyl isomerase activity is not required for TOR binding.","method":"Yeast two-hybrid (rapamycin-dependent), site-directed mutagenesis, rapamycin-resistance assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — two-hybrid plus mutagenesis plus in vivo resistance phenotype, replicated across multiple labs","pmids":["7499212","7528205"],"is_preprint":false},{"year":1995,"finding":"FKBP12 undergoes upregulation during nerve regeneration (not degeneration) with a time course paralleling GAP-43 mRNA; FKBP12 is rapidly axonally transported at rates similar to GAP-43 following sciatic nerve crush.","method":"In situ hybridization, nerve crush models, axonal transport measurements","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — localization and expression correlating with regeneration-specific context, direct transport measurements","pmids":["7536825"],"is_preprint":false},{"year":1995,"finding":"Immunophilins CyclophilinA and FKBP12 interact with transcription factor YY1 in yeast two-hybrid and in mammalian cells; cyclosporin A and FK506 disrupt these interactions respectively; overexpression of FKBP12 alters YY1-regulated transcription in a promoter-dependent manner.","method":"Yeast two-hybrid, co-immunoprecipitation in mammalian cells, transcription reporter assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two-hybrid validated by Co-IP in mammalian cells with functional transcriptional readout, single lab","pmids":["7541038"],"is_preprint":false},{"year":2002,"finding":"FKBP12 modulates the binding of RyR1 to the II-III loop of the dihydropyridine receptor (DHPR): FKBP12 potentiates RyR1 binding to the Thr671-Leu690 domain of DHPR alpha1-subunit with EC50 of 10 nM, and this potentiation is inhibited by rapamycin or FK506. Removal of FKBP12 from RyR1 abolishes the DHPR domain A-induced increase in RyR1 open probability.","method":"Surface plasmon resonance, polystyrene bead binding assays, single-channel lipid bilayer electrophysiology","journal":"Biophysical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding measurement plus functional channel assay, single lab","pmids":["11751303"],"is_preprint":false}],"current_model":"FKBP1A (FKBP12) is a cytoplasmic cis-trans peptidyl-prolyl isomerase that functions as a molecular scaffold: it binds FK506 and rapamycin with high affinity (defined by atomic crystal structures), forming ternary complexes that inhibit calcineurin (with FK506) or recruit and inhibit mTOR/FRAP (with rapamycin); it constitutively binds and stabilizes the skeletal muscle ryanodine receptor (RyR1) at Val2461 in a PPIase-independent manner to suppress aberrant Ca2+ release and enhance EC coupling gain; it serves as a gatekeeper of TGF-beta family type I receptors (including ALK2, ALK4, TbetaR-I) by occupying their GS-domain Leu-Pro motif to prevent ligand-independent signaling; it anchors calcineurin to the IP3R; it endogenously regulates calcineurin's phosphoproteome; it suppresses EGFR autophosphorylation; it promotes MDM2 self-ubiquitination to activate p53; it mediates necroptotic RIPK1-RIPK3-MLKL signaling; and in endocardial cells it negatively regulates Notch1 stability to control ventricular trabeculation, with loss of FKBP12 causing dilated cardiomyopathy and hypertrabeculation."},"narrative":{"mechanistic_narrative":"FKBP1A (FKBP12) is a small cytoplasmic peptidyl-prolyl isomerase whose dominant biological role is as a high-affinity ligand-binding scaffold and a constitutive regulator of membrane receptor and channel complexes [PMID:7678431, PMID:7518616]. Its defining pharmacological property is binding the immunosuppressant FK506 and the macrolide rapamycin within a cavity formed by its five-stranded beta-sheet, alpha-helix and three loops [PMID:7678431]; the resulting drug-bound complexes act as composite surfaces that engage second targets. The FKBP12-FK506 complex docks onto calcineurin, displacing its autoinhibitory element through surface residues Asp37, Arg42 and His87 to block phosphatase activity independently of PPIase function [PMID:8524402, PMID:1379588], and FKBP12 is the unique family member required for FK506-mediated T-cell suppression [PMID:12085010]. The FKBP12-rapamycin complex instead binds the FRB domain of mTOR/FRAP at a serine-gated pocket (Ser2035), with rapamycin bridging two hydrophobic surfaces to dimerize the proteins [PMID:7518356, PMID:7822316, PMID:8662507, PMID:10089303, PMID:7499212, PMID:7528205]; loss of FKBP12 in brain derepresses mTOR-Raptor signaling and S6K phosphorylation [PMID:19081378]. Independently of drugs, FKBP12 occupies a Leu-Pro motif adjacent to the activating phosphorylation sites of TGF-beta family type I receptors, holding ligand-free receptors silent until type II receptor-mediated phosphorylation releases it [PMID:8756725, PMID:9233797]; this gatekeeper role extends to BMP receptor ALK2, where FKBP12 suppresses ligand-independent and gain-of-function signaling that drives hepcidin expression and FOP-associated mutations [PMID:28864813, PMID:29551750], and to ALK4, where re-association recruits the Smad7-Smurf1 ubiquitination machinery [PMID:16720724]. FKBP12 also constitutively and stoichiometrically binds the ryanodine receptors via a hydrophobic cluster in the SPRY1 domain and the critical RyR1 residue Val2461, stabilizing the closed channel state and tuning Ca2+ release and excitation-contraction coupling gain in a PPIase-independent manner [PMID:7531689, PMID:11279144, PMID:12704193, PMID:26245150, PMID:28536302]. Genetic ablation reveals physiological consequences across tissues: global loss causes dilated cardiomyopathy with hypertrabeculation/noncompaction and disordered ryanodine receptor Ca2+ release [PMID:9461216], and endocardial-specific loss recapitulates this phenotype by stabilizing activated Notch1 [PMID:23571217]. Additional regulatory targets include the IP3R, to which FKBP12 anchors calcineurin [PMID:9346894], the EGFR kinase domain whose autophosphorylation it suppresses [PMID:22103444], MDM2 self-ubiquitination promoting p53 activation [PMID:27617579], and the RIPK1-RIPK3-MLKL necroptotic pathway [PMID:31028177].","teleology":[{"year":1993,"claim":"Establishing the atomic architecture of FKBP12 and how it captures FK506 and rapamycin defined the structural basis for all of its drug-mediated functions.","evidence":"High-resolution X-ray crystallography of FKBP12-FK506 and FKBP12-rapamycin complexes","pmids":["7678431"],"confidence":"High","gaps":["Structure alone did not establish the cellular target of either drug complex","PPIase catalytic mechanism inferred but not functionally dissected"]},{"year":1994,"claim":"Identifying that FKBP12 binds type I TGF-beta receptors and, separately, the mTOR target revealed that FKBP12 has both drug-dependent and drug-independent receptor partners.","evidence":"Yeast two-hybrid plus Co-IP for TGF-beta receptors; FKBP12-rapamycin affinity purification of RAFT1/mTOR","pmids":["7518616","7518356","7822316"],"confidence":"High","gaps":["Functional consequence of receptor binding not yet defined","Binding sites on receptors unmapped"]},{"year":1995,"claim":"Mapping the FRB domain and the Ser2035 gating residue on mTOR, and the calcineurin contact residues on FKBP12, defined how the ternary drug complexes select and inhibit their targets.","evidence":"Proteolysis mapping/mutagenesis of mTOR FRB; crystallography plus mutagenesis of FKBP12-FK506-calcineurin; rapamycin-resistance two-hybrid","pmids":["7539137","8524402","1379588","7499212","7528205"],"confidence":"High","gaps":["Whether PPIase activity contributes to target engagement (later shown dispensable)","In vivo selectivity of calcineurin inhibition not yet measured"]},{"year":1995,"claim":"Demonstrating stoichiometric FKBP12 binding to RyR1 and PPIase-independent channel modulation established FKBP12 as a constitutive structural regulator of Ca2+ release channels.","evidence":"Exchange binding assays, Ca2+ flux measurements, PPIase-dead mutagenesis on skeletal muscle RyR1","pmids":["7531689"],"confidence":"High","gaps":["Precise RyR1 binding epitope not yet identified","Physiological role of channel stabilization untested in vivo"]},{"year":1996,"claim":"Defining FKBP12 as a phosphorylation-released gatekeeper of TGF-beta type I receptors and resolving the FKBP12-rapamycin-FRB ternary structure clarified the mechanistic logic of both its receptor-silencing and drug-bridging functions.","evidence":"Co-IP, FKBP12 point mutants, myristylated overexpression assays; 2.7 A ternary complex crystallography","pmids":["8756725","8662507","10089303","8702774"],"confidence":"High","gaps":["Generalization across all type I receptors initially incomplete","RyR isoform selectivity mechanism unresolved"]},{"year":1997,"claim":"Pinpointing the Leu-Pro receptor motif engaged by the FKBP12 rapamycin pocket explained how it inhibits type I receptor phosphorylation and how rapamycin reverses this, and extended the anchoring role to the IP3R-calcineurin axis.","evidence":"Reciprocal mutagenesis of FKBP12 and TbetaR-I with kinase assays; mutagenesis/Co-IP mapping on IP3R","pmids":["9233797","9346894"],"confidence":"High","gaps":["IP3R-calcineurin functional output (Co-IP-based, single lab) not quantified","Receptor occupancy dynamics in vivo unclear"]},{"year":1998,"claim":"Genetic ablation showed FKBP12 is physiologically essential for cardiac development and ryanodine receptor regulation while being dispensable for TGF-beta signaling in vivo, separating its developmental and pharmacological roles.","evidence":"Conditional knockout mice with cardiac phenotyping and Ca2+ release measurements","pmids":["9461216"],"confidence":"High","gaps":["Cell type driving cardiomyopathy not yet localized","Molecular link between FKBP12 loss and the developmental defect undefined"]},{"year":2001,"claim":"Identifying RyR1 Val2461 as the binding-critical residue and showing FKBP12 loss derepresses TGF-beta receptor signaling toward p21/p38-driven G1 arrest linked structural binding determinants to discrete physiological outputs.","evidence":"RyR1 site-directed mutagenesis with single-channel electrophysiology; FKBP12-/- cells with dominant-negative receptor and p38 epistasis","pmids":["11279144","11226255"],"confidence":"High","gaps":["How Val2461 substitution alters gating mechanistically not fully resolved","Selectivity of p38 versus SMAD branch downstream of receptor over-signaling"]},{"year":2003,"claim":"Functional studies established that FKBP12 binding sets skeletal EC coupling gain and that FKBP12.6 dissociation underlies exercise-induced cardiac arrhythmia, connecting channel occupancy to muscle physiology.","evidence":"RyR1 mutant rescue in dyspedic myotubes with voltage-clamp fluorometry; FKBP12.6 knockout mice with exercise challenge and single-channel recordings","pmids":["12704193","12837242"],"confidence":"High","gaps":["Whether PKA phosphorylation truly dissociates FKBP12.6 was later contested","Quantitative contribution of FKBP12 to in vivo EC coupling gain"]},{"year":2004,"claim":"A rigorous negative result showed PKA phosphorylation at RyR2 Ser2808 does not dissociate FKBP12.6, refining the model of how phosphorylation and FKBP occupancy interact.","evidence":"Phospho-specific antibodies and Co-IP with recombinant and native RyR2, phosphomimetic mutant","pmids":["14715536"],"confidence":"High","gaps":["Reconciliation with earlier dissociation claims unresolved","Alternative regulators of FKBP12.6-RyR2 affinity not defined here"]},{"year":2008,"claim":"Brain-specific deletion demonstrated FKBP12 restrains mTOR-Raptor signaling and translation-dependent synaptic plasticity and behavior in vivo, generalizing its negative-regulator role beyond drug-bound contexts.","evidence":"Conditional brain knockout with mTOR-Raptor Co-IP, LTP electrophysiology and behavioral assays","pmids":["19081378"],"confidence":"High","gaps":["Direct biochemical mechanism of mTOR inhibition by endogenous FKBP12 undefined","Rapamycin-resistant LTP component not mechanistically resolved"]},{"year":2013,"claim":"Cell-type-specific ablation localized the cardiomyopathy to endocardium and identified Notch1 stabilization as the causal mechanism, resolving the long-standing developmental phenotype.","evidence":"Endothelial- versus cardiomyocyte-specific Cre knockout with N1ICD stability assays and Notch inhibition rescue","pmids":["23571217"],"confidence":"High","gaps":["Direct physical mechanism by which FKBP12 destabilizes N1ICD not shown","Whether PPIase activity is involved unaddressed"]},{"year":2015,"claim":"High-resolution structural work on the RyR SPRY1 domain and cryo-EM of the RyR2-FKBP12.6 complex defined the binding interface and the conformational mechanism of channel stabilization.","evidence":"SPRY1 crystallography with FRET and mutagenesis; cryo-EM of RyR2-FKBP12.6 with atomic modeling","pmids":["26245150","28536302"],"confidence":"High","gaps":["Resolution insufficient to model side-chain contacts at the interface","Link between FKBP occupancy and the P2-domain phosphorylation conformations inferred from structure"]},{"year":2017,"claim":"Expanding FKBP12 to BMP receptor ALK2/hepcidin control and to endogenous calcineurin substrate selectivity broadened its gatekeeper and phosphatase-targeting roles into iron homeostasis and neurodegeneration.","evidence":"Pharmacologic and genetic ALK2 binding-deficient mutants with SMAD/hepcidin assays; quantitative phosphoproteomics with a rat PD model","pmids":["28864813","29229832"],"confidence":"High","gaps":["Whether calcineurin substrate selectivity is direct or via anchoring not fully resolved","Therapeutic window of FKBP12-calcineurin disruption undefined"]},{"year":2019,"claim":"Loss-of-function studies placed FKBP12 within necroptotic RIPK1-RIPK3-MLKL signaling, adding a programmed cell death role to its repertoire.","evidence":"siRNA/shRNA knockdown with TNF-induced necroptosis assays and necrosome western blots","pmids":["31028177"],"confidence":"Medium","gaps":["Whether FKBP12 directly binds RIPK1/RIPK3 not demonstrated","Single lab; mechanism of necrosome regulation incompletely resolved"]},{"year":2025,"claim":"Discovery of fully synthetic FKBP12-mTOR molecular glues showed the FKBP12-FRB interface can be re-engineered with non-rapamycin chemotypes, extending its scaffold function to designed proximity inducers.","evidence":"Biochemical screening, ternary complex crystallography and cell-based FKBP12-FRB dimerization assays","pmids":["39916884"],"confidence":"High","gaps":["Downstream functional consequences of synthetic dimerization in vivo untested","Selectivity across FKBP family not established"]},{"year":null,"claim":"How FKBP12 mechanistically distinguishes and switches among its many partners (receptors, channels, phosphatases, ubiquitin ligases, death-signaling kinases) within a single cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model for partner selection or competition","Role of PPIase activity in most non-channel functions undefined","Direct structural mechanism of Notch1, MDM2 and necrosome regulation lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016853","term_label":"isomerase activity","supporting_discovery_ids":[0,10]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[6,7,21]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,6,10,27]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[8,20]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,1]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[31]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[5,6,7]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,6,7,21,18]},{"term_id":"R-HSA-397014","term_label":"Muscle contraction","supporting_discovery_ids":[10,17,12]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[9,19]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[4,25]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[23,24]}],"complexes":["FKBP12-rapamycin-mTOR/FRB ternary complex","FKBP12-FK506-calcineurin complex","RyR1/RyR2-FKBP12 channel complex","Smad7-Smurf1-ALK4 complex"],"partners":["MTOR","PPP3CA","RYR1","RYR2","TGFBR1","ACVR1","ITPR1","EGFR"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P62942","full_name":"Peptidyl-prolyl cis-trans isomerase FKBP1A","aliases":["12 kDa FK506-binding protein","12 kDa FKBP","FKBP-12","Calstabin-1","FK506-binding protein 1A","FKBP-1A","Immunophilin FKBP12","Rotamase"],"length_aa":108,"mass_kda":12.0,"function":"Keeps in an inactive conformation TGFBR1, the TGF-beta type I serine/threonine kinase receptor, preventing TGF-beta receptor activation in absence of ligand. Recruits SMAD7 to ACVR1B which prevents the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. May modulate the RYR1 calcium channel activity. PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides","subcellular_location":"Cytoplasm, cytosol; Sarcoplasmic reticulum membrane","url":"https://www.uniprot.org/uniprotkb/P62942/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FKBP1A","classification":"Not Classified","n_dependent_lines":265,"n_total_lines":1047,"dependency_fraction":0.2531041069723018},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FKBP1A","total_profiled":1310},"omim":[{"mim_id":"617076","title":"FK506-BINDING PROTEIN-LIKE; FKBPL","url":"https://www.omim.org/entry/617076"},{"mim_id":"614505","title":"FK506-BINDING PROTEIN 14; FKBP14","url":"https://www.omim.org/entry/614505"},{"mim_id":"611723","title":"CHROMOSOME 21 OPEN READING FRAME 24; C21ORF24","url":"https://www.omim.org/entry/611723"},{"mim_id":"610571","title":"FK506-BINDING PROTEIN 11; FKBP11","url":"https://www.omim.org/entry/610571"},{"mim_id":"607062","title":"FK506-BINDING PROTEIN 7; FKBP7","url":"https://www.omim.org/entry/607062"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"},{"location":"Primary cilium","reliability":"Additional"},{"location":"Basal body","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/FKBP1A"},"hgnc":{"alias_symbol":["FKBP-12","FKBP12","PKC12","PPIASE","FKBP12C"],"prev_symbol":["FKBP1"]},"alphafold":{"accession":"P62942","domains":[{"cath_id":"3.10.50.40","chopping":"2-106","consensus_level":"high","plddt":96.6442,"start":2,"end":106}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P62942","model_url":"https://alphafold.ebi.ac.uk/files/AF-P62942-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P62942-F1-predicted_aligned_error_v6.png","plddt_mean":96.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FKBP1A","jax_strain_url":"https://www.jax.org/strain/search?query=FKBP1A"},"sequence":{"accession":"P62942","fasta_url":"https://rest.uniprot.org/uniprotkb/P62942.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P62942/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P62942"}},"corpus_meta":[{"pmid":"7518356","id":"PMC_7518356","title":"RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs.","date":"1994","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/7518356","citation_count":1264,"is_preprint":false},{"pmid":"7678431","id":"PMC_7678431","title":"Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin.","date":"1993","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7678431","citation_count":1082,"is_preprint":false},{"pmid":"7822316","id":"PMC_7822316","title":"Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7822316","citation_count":735,"is_preprint":false},{"pmid":"8662507","id":"PMC_8662507","title":"Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP.","date":"1996","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8662507","citation_count":734,"is_preprint":false},{"pmid":"8524402","id":"PMC_8524402","title":"Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex.","date":"1995","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8524402","citation_count":632,"is_preprint":false},{"pmid":"12837242","id":"PMC_12837242","title":"FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death.","date":"2003","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/12837242","citation_count":613,"is_preprint":false},{"pmid":"7539137","id":"PMC_7539137","title":"Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7539137","citation_count":456,"is_preprint":false},{"pmid":"10200280","id":"PMC_10200280","title":"Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10200280","citation_count":422,"is_preprint":false},{"pmid":"9461216","id":"PMC_9461216","title":"Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12.","date":"1998","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9461216","citation_count":350,"is_preprint":false},{"pmid":"8756725","id":"PMC_8756725","title":"The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors.","date":"1996","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8756725","citation_count":326,"is_preprint":false},{"pmid":"7518616","id":"PMC_7518616","title":"Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12.","date":"1994","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7518616","citation_count":312,"is_preprint":false},{"pmid":"9233797","id":"PMC_9233797","title":"Mechanism of TGFbeta receptor inhibition by FKBP12.","date":"1997","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9233797","citation_count":295,"is_preprint":false},{"pmid":"10702316","id":"PMC_10702316","title":"FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10702316","citation_count":275,"is_preprint":false},{"pmid":"11907581","id":"PMC_11907581","title":"Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy.","date":"2002","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/11907581","citation_count":245,"is_preprint":false},{"pmid":"8702774","id":"PMC_8702774","title":"Selective binding of FKBP12.6 by the cardiac ryanodine receptor.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8702774","citation_count":220,"is_preprint":false},{"pmid":"7499212","id":"PMC_7499212","title":"TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7499212","citation_count":212,"is_preprint":false},{"pmid":"11930000","id":"PMC_11930000","title":"FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11930000","citation_count":210,"is_preprint":false},{"pmid":"9346894","id":"PMC_9346894","title":"FKBP12 binds the inositol 1,4,5-trisphosphate receptor at leucine-proline (1400-1401) and anchors calcineurin to this FK506-like domain.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9346894","citation_count":189,"is_preprint":false},{"pmid":"19081378","id":"PMC_19081378","title":"Removal of FKBP12 enhances mTOR-Raptor interactions, LTP, memory, and perseverative/repetitive behavior.","date":"2008","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/19081378","citation_count":183,"is_preprint":false},{"pmid":"11114166","id":"PMC_11114166","title":"Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-associated protein is involved in rapamycin-sensitive signaling and translation initiation.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11114166","citation_count":176,"is_preprint":false},{"pmid":"1371107","id":"PMC_1371107","title":"The Hsp56 component of steroid receptor complexes binds to immobilized FK506 and shows homology to FKBP-12 and FKBP-13.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1371107","citation_count":169,"is_preprint":false},{"pmid":"11279144","id":"PMC_11279144","title":"FKBP12 binding modulates ryanodine receptor channel gating.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11279144","citation_count":142,"is_preprint":false},{"pmid":"14715536","id":"PMC_14715536","title":"Protein kinase A phosphorylation at serine-2808 of the cardiac Ca2+-release channel (ryanodine receptor) does not dissociate 12.6-kDa FK506-binding protein (FKBP12.6).","date":"2004","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/14715536","citation_count":137,"is_preprint":false},{"pmid":"10330150","id":"PMC_10330150","title":"Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans.","date":"1999","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10330150","citation_count":133,"is_preprint":false},{"pmid":"14578359","id":"PMC_14578359","title":"FKBP12-rapamycin-associated protein or mammalian target of rapamycin (FRAP/mTOR) localization in the endoplasmic reticulum and the Golgi apparatus.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14578359","citation_count":129,"is_preprint":false},{"pmid":"7531689","id":"PMC_7531689","title":"Characterization of an exchange reaction between soluble FKBP-12 and the FKBP.ryanodine receptor complex. Modulation by FKBP mutants deficient in peptidyl-prolyl isomerase activity.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7531689","citation_count":127,"is_preprint":false},{"pmid":"9344552","id":"PMC_9344552","title":"A nonimmunosuppressant FKBP-12 ligand increases nerve regeneration.","date":"1997","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/9344552","citation_count":126,"is_preprint":false},{"pmid":"11157671","id":"PMC_11157671","title":"Overexpression of FK506-binding protein FKBP12.6 in cardiomyocytes reduces ryanodine receptor-mediated Ca(2+) leak from the sarcoplasmic reticulum and increases contractility.","date":"2001","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/11157671","citation_count":124,"is_preprint":false},{"pmid":"9933627","id":"PMC_9933627","title":"The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9933627","citation_count":123,"is_preprint":false},{"pmid":"7536825","id":"PMC_7536825","title":"Neuronal regeneration enhances the expression of the immunophilin FKBP-12.","date":"1995","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/7536825","citation_count":121,"is_preprint":false},{"pmid":"11226255","id":"PMC_11226255","title":"FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11226255","citation_count":118,"is_preprint":false},{"pmid":"10089303","id":"PMC_10089303","title":"Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A resolution.","date":"1999","source":"Acta crystallographica. Section D, Biological crystallography","url":"https://pubmed.ncbi.nlm.nih.gov/10089303","citation_count":116,"is_preprint":false},{"pmid":"11600372","id":"PMC_11600372","title":"Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR.","date":"2001","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/11600372","citation_count":114,"is_preprint":false},{"pmid":"8846782","id":"PMC_8846782","title":"FKBP12-rapamycin target TOR2 is a vacuolar protein with an associated phosphatidylinositol-4 kinase activity.","date":"1995","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8846782","citation_count":113,"is_preprint":false},{"pmid":"7528205","id":"PMC_7528205","title":"Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7528205","citation_count":111,"is_preprint":false},{"pmid":"12702575","id":"PMC_12702575","title":"Overexpression of the EGFR/FKBP12/HIF-2alpha pathway identified in childhood astrocytomas by angiogenesis gene profiling.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12702575","citation_count":110,"is_preprint":false},{"pmid":"1379588","id":"PMC_1379588","title":"Charged surface residues of FKBP12 participate in formation of the FKBP12-FK506-calcineurin complex.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1379588","citation_count":105,"is_preprint":false},{"pmid":"26639422","id":"PMC_26639422","title":"BK Polyomavirus Replication in Renal Tubular Epithelial Cells Is Inhibited by Sirolimus, but Activated by Tacrolimus Through a Pathway Involving FKBP-12.","date":"2015","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/26639422","citation_count":99,"is_preprint":false},{"pmid":"10438630","id":"PMC_10438630","title":"Folding pathway of FKBP12 and characterisation of the transition state.","date":"1999","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10438630","citation_count":93,"is_preprint":false},{"pmid":"15998242","id":"PMC_15998242","title":"Effects of S-glutathionylation and S-nitrosylation on calmodulin binding to triads and FKBP12 binding to type 1 calcium release channels.","date":"2005","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/15998242","citation_count":87,"is_preprint":false},{"pmid":"7541038","id":"PMC_7541038","title":"Cyclophilin A and FKBP12 interact with YY1 and alter its transcriptional activity.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7541038","citation_count":86,"is_preprint":false},{"pmid":"12231510","id":"PMC_12231510","title":"The FKBP12-rapamycin-associated protein (FRAP) is a CLIP-170 kinase.","date":"2002","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/12231510","citation_count":86,"is_preprint":false},{"pmid":"31537789","id":"PMC_31537789","title":"Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agents.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31537789","citation_count":86,"is_preprint":false},{"pmid":"7503980","id":"PMC_7503980","title":"Rapamycin-FKBP12 blocks proliferation, induces differentiation, and inhibits cdc2 kinase activity in a myogenic cell line.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7503980","citation_count":84,"is_preprint":false},{"pmid":"16405911","id":"PMC_16405911","title":"Structural characterization of the RyR1-FKBP12 interaction.","date":"2005","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16405911","citation_count":78,"is_preprint":false},{"pmid":"23571217","id":"PMC_23571217","title":"Fkbp1a controls ventricular myocardium trabeculation and compaction by regulating endocardial Notch1 activity.","date":"2013","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/23571217","citation_count":75,"is_preprint":false},{"pmid":"7673106","id":"PMC_7673106","title":"The rapamycin and FKBP12 target (RAFT) displays phosphatidylinositol 4-kinase activity.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7673106","citation_count":71,"is_preprint":false},{"pmid":"30981837","id":"PMC_30981837","title":"LncRNA SNHG15 acts as an oncogene in prostate cancer by regulating miR-338-3p/FKBP1A axis.","date":"2019","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/30981837","citation_count":67,"is_preprint":false},{"pmid":"12704193","id":"PMC_12704193","title":"FKBP12 binding to RyR1 modulates excitation-contraction coupling in mouse skeletal myotubes.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12704193","citation_count":61,"is_preprint":false},{"pmid":"18704951","id":"PMC_18704951","title":"Structural coupling between FKBP12 and buried water.","date":"2009","source":"Proteins","url":"https://pubmed.ncbi.nlm.nih.gov/18704951","citation_count":59,"is_preprint":false},{"pmid":"26245150","id":"PMC_26245150","title":"Crystal structures of ryanodine receptor SPRY1 and tandem-repeat domains reveal a critical FKBP12 binding determinant.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26245150","citation_count":59,"is_preprint":false},{"pmid":"15271664","id":"PMC_15271664","title":"FKBP12.6 overexpression decreases Ca2+ spark amplitude but enhances [Ca2+]i transient in rat cardiac myocytes.","date":"2004","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15271664","citation_count":58,"is_preprint":false},{"pmid":"14766396","id":"PMC_14766396","title":"The immunophilin FKBP12: a molecular guardian of the TGF-beta family type I receptors.","date":"2004","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/14766396","citation_count":57,"is_preprint":false},{"pmid":"22363773","id":"PMC_22363773","title":"FKBP12 activates the cardiac ryanodine receptor Ca2+-release channel and is antagonised by FKBP12.6.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22363773","citation_count":56,"is_preprint":false},{"pmid":"28864813","id":"PMC_28864813","title":"The immunophilin FKBP12 inhibits hepcidin expression by binding the BMP type I receptor ALK2 in hepatocytes.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28864813","citation_count":55,"is_preprint":false},{"pmid":"16720724","id":"PMC_16720724","title":"FKBP12 functions as an adaptor of the Smad7-Smurf1 complex on activin type I receptor.","date":"2006","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/16720724","citation_count":54,"is_preprint":false},{"pmid":"11897558","id":"PMC_11897558","title":"Ryanodine receptors, FKBP12, and heart failure.","date":"2002","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/11897558","citation_count":53,"is_preprint":false},{"pmid":"23887639","id":"PMC_23887639","title":"Sirolimus-FKBP12.6 impairs endothelial barrier function through protein kinase C-α activation and disruption of the p120-vascular endothelial cadherin interaction.","date":"2013","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23887639","citation_count":52,"is_preprint":false},{"pmid":"14966299","id":"PMC_14966299","title":"Over-expression of FK506-binding protein FKBP12.6 alters excitation-contraction coupling in adult rabbit cardiomyocytes.","date":"2004","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/14966299","citation_count":49,"is_preprint":false},{"pmid":"15591045","id":"PMC_15591045","title":"Interaction of FKBP12.6 with the cardiac ryanodine receptor C-terminal domain.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15591045","citation_count":49,"is_preprint":false},{"pmid":"15036951","id":"PMC_15036951","title":"Role of FKBP12.6 in hypoxia- and norepinephrine-induced Ca2+ release and contraction in pulmonary artery myocytes.","date":"2004","source":"Cell calcium","url":"https://pubmed.ncbi.nlm.nih.gov/15036951","citation_count":46,"is_preprint":false},{"pmid":"12231433","id":"PMC_12231433","title":"Neuroprotective and antioxidant properties of FKBP-binding immunophilin ligands are independent on the FKBP12 pathway in human cells.","date":"2002","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/12231433","citation_count":43,"is_preprint":false},{"pmid":"12085010","id":"PMC_12085010","title":"FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506.","date":"2002","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/12085010","citation_count":42,"is_preprint":false},{"pmid":"17478757","id":"PMC_17478757","title":"Removal of FKBP12/12.6 from endothelial ryanodine receptors leads to an intracellular calcium leak and endothelial dysfunction.","date":"2007","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17478757","citation_count":42,"is_preprint":false},{"pmid":"19578067","id":"PMC_19578067","title":"Dissociation of FKBP12.6 from ryanodine receptor type 2 is regulated by cyclic ADP-ribose but not beta-adrenergic stimulation in mouse cardiomyocytes.","date":"2009","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/19578067","citation_count":40,"is_preprint":false},{"pmid":"28536302","id":"PMC_28536302","title":"A cryo-EM-based model of phosphorylation- and FKBP12.6-mediated allosterism of the cardiac ryanodine receptor.","date":"2017","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/28536302","citation_count":40,"is_preprint":false},{"pmid":"15470257","id":"PMC_15470257","title":"FKBP12 controls aspartate pathway flux in Saccharomyces cerevisiae to prevent toxic intermediate accumulation.","date":"2004","source":"Eukaryotic cell","url":"https://pubmed.ncbi.nlm.nih.gov/15470257","citation_count":39,"is_preprint":false},{"pmid":"18466757","id":"PMC_18466757","title":"FKBP12.6 disruption impairs glucose-induced insulin secretion.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18466757","citation_count":37,"is_preprint":false},{"pmid":"27917191","id":"PMC_27917191","title":"Tomato FK506 Binding Protein 12KD (FKBP12) Mediates the Interaction between Rapamycin and Target of Rapamycin (TOR).","date":"2016","source":"Frontiers in plant science","url":"https://pubmed.ncbi.nlm.nih.gov/27917191","citation_count":37,"is_preprint":false},{"pmid":"9662508","id":"PMC_9662508","title":"TGF-beta-signaling with small molecule FKBP12 antagonists that bind myristoylated FKBP12-TGF-beta type I receptor fusion proteins.","date":"1998","source":"Chemistry & biology","url":"https://pubmed.ncbi.nlm.nih.gov/9662508","citation_count":36,"is_preprint":false},{"pmid":"29229832","id":"PMC_29229832","title":"FKBP12 contributes to α-synuclein toxicity by regulating the calcineurin-dependent phosphoproteome.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29229832","citation_count":36,"is_preprint":false},{"pmid":"19414059","id":"PMC_19414059","title":"A peptidyl-prolyl isomerase, FKBP12, accumulates in Alzheimer neurofibrillary tangles.","date":"2009","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/19414059","citation_count":36,"is_preprint":false},{"pmid":"9315655","id":"PMC_9315655","title":"FKBP12 physically and functionally interacts with aspartokinase in Saccharomyces cerevisiae.","date":"1997","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9315655","citation_count":33,"is_preprint":false},{"pmid":"11751303","id":"PMC_11751303","title":"FKBP12 modulation of the binding of the skeletal ryanodine receptor onto the II-III loop of the dihydropyridine receptor.","date":"2002","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/11751303","citation_count":33,"is_preprint":false},{"pmid":"12600203","id":"PMC_12600203","title":"Energetic and structural analysis of the role of tryptophan 59 in FKBP12.","date":"2003","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12600203","citation_count":33,"is_preprint":false},{"pmid":"27617579","id":"PMC_27617579","title":"FKBP12 enhances sensitivity to chemotherapy-induced cancer cell apoptosis by inhibiting MDM2.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27617579","citation_count":32,"is_preprint":false},{"pmid":"32669538","id":"PMC_32669538","title":"Rieske iron-sulfur protein induces FKBP12.6/RyR2 complex remodeling and subsequent pulmonary hypertension through NF-κB/cyclin D1 pathway.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32669538","citation_count":32,"is_preprint":false},{"pmid":"19661110","id":"PMC_19661110","title":"A mechanism of ryanodine receptor modulation by FKBP12/12.6, protein kinase A, and K201.","date":"2010","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/19661110","citation_count":32,"is_preprint":false},{"pmid":"25347864","id":"PMC_25347864","title":"Eccentric contractions disrupt FKBP12 content in mouse skeletal muscle.","date":"2014","source":"Physiological reports","url":"https://pubmed.ncbi.nlm.nih.gov/25347864","citation_count":30,"is_preprint":false},{"pmid":"9362068","id":"PMC_9362068","title":"Functions of FKBP12 and mitochondrial cyclophilin active site residues in vitro and in vivo in Saccharomyces cerevisiae.","date":"1997","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/9362068","citation_count":30,"is_preprint":false},{"pmid":"33138677","id":"PMC_33138677","title":"LncRNA AFAP1-AS1 modulates the sensitivity of paclitaxel-resistant prostate cancer cells to paclitaxel via miR-195-5p/FKBP1A axis.","date":"2020","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33138677","citation_count":29,"is_preprint":false},{"pmid":"31028177","id":"PMC_31028177","title":"FKBP12 mediates necroptosis by initiating RIPK1-RIPK3-MLKL signal transduction in response to TNF receptor 1 ligation.","date":"2019","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/31028177","citation_count":28,"is_preprint":false},{"pmid":"29551750","id":"PMC_29551750","title":"Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.","date":"2018","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/29551750","citation_count":28,"is_preprint":false},{"pmid":"31908154","id":"PMC_31908154","title":"Tacrolimus-induced hypomagnesemia and hypercalciuria requires FKBP12 suggesting a role for calcineurin.","date":"2020","source":"Physiological reports","url":"https://pubmed.ncbi.nlm.nih.gov/31908154","citation_count":26,"is_preprint":false},{"pmid":"8325502","id":"PMC_8325502","title":"The tyrosine89 residue of yeast FKBP12 is required for rapamycin binding.","date":"1993","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8325502","citation_count":26,"is_preprint":false},{"pmid":"25053409","id":"PMC_25053409","title":"Ligands for FKBP12 increase Ca2+ influx and protein synthesis to improve skeletal muscle function.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25053409","citation_count":25,"is_preprint":false},{"pmid":"8062824","id":"PMC_8062824","title":"Streptomyces chrysomallus FKBP-33 is a novel immunophilin consisting of two FK506 binding domains; its gene is transcriptionally coupled to the FKBP-12 gene.","date":"1994","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8062824","citation_count":25,"is_preprint":false},{"pmid":"14970260","id":"PMC_14970260","title":"The 12 kDa FK506-binding protein, FKBP12, modulates the Ca(2+)-flux properties of the type-3 ryanodine receptor.","date":"2004","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/14970260","citation_count":25,"is_preprint":false},{"pmid":"34662453","id":"PMC_34662453","title":"Tacrolimus ameliorates podocyte injury by restoring FK506 binding protein 12 (FKBP12) at actin cytoskeleton.","date":"2021","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/34662453","citation_count":24,"is_preprint":false},{"pmid":"17877381","id":"PMC_17877381","title":"Increased striatal mRNA and protein levels of the immunophilin FKBP-12 in experimental Parkinson's disease and identification of FKBP-12-binding proteins.","date":"2007","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/17877381","citation_count":24,"is_preprint":false},{"pmid":"26229292","id":"PMC_26229292","title":"Molecular Docking studies of FKBP12-mTOR inhibitors using binding predictions.","date":"2015","source":"Bioinformation","url":"https://pubmed.ncbi.nlm.nih.gov/26229292","citation_count":24,"is_preprint":false},{"pmid":"23973485","id":"PMC_23973485","title":"Expression of budding yeast FKBP12 confers rapamycin susceptibility to the unicellular red alga Cyanidioschyzon merolae.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23973485","citation_count":22,"is_preprint":false},{"pmid":"39916884","id":"PMC_39916884","title":"Discovery of fully synthetic FKBP12-mTOR molecular glues.","date":"2025","source":"Chemical science","url":"https://pubmed.ncbi.nlm.nih.gov/39916884","citation_count":22,"is_preprint":false},{"pmid":"12502928","id":"PMC_12502928","title":"Expression of FKBP12 in benign and malignant vascular endothelium: an immunohistochemical study on conventional sections and tissue microarrays.","date":"2003","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12502928","citation_count":22,"is_preprint":false},{"pmid":"18611397","id":"PMC_18611397","title":"Endothelin receptor antagonist CPU0213 and vitamin E reverse downregulation of FKBP12.6 and SERCA2a: a role of hyperphosphorylation of PKCepsilon.","date":"2008","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18611397","citation_count":21,"is_preprint":false},{"pmid":"26009182","id":"PMC_26009182","title":"Bcl-2 and FKBP12 bind to IP3 and ryanodine receptors at overlapping sites: the complexity of protein-protein interactions for channel regulation.","date":"2015","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/26009182","citation_count":20,"is_preprint":false},{"pmid":"26366742","id":"PMC_26366742","title":"Characterization of the FKBP12-Encoding Genes in Aspergillus fumigatus.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26366742","citation_count":19,"is_preprint":false},{"pmid":"16176935","id":"PMC_16176935","title":"Ryanodine receptor binding to FKBP12 is modulated by channel activation state.","date":"2005","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/16176935","citation_count":19,"is_preprint":false},{"pmid":"18511525","id":"PMC_18511525","title":"FKBP12 deficiency reduces strength deficits after eccentric contraction-induced muscle injury.","date":"2008","source":"Journal of applied physiology (Bethesda, Md. : 1985)","url":"https://pubmed.ncbi.nlm.nih.gov/18511525","citation_count":18,"is_preprint":false},{"pmid":"22103444","id":"PMC_22103444","title":"Suppression of EGFR autophosphorylation by FKBP12.","date":"2011","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22103444","citation_count":18,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52593,"output_tokens":9378,"usd":0.149225,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18979,"output_tokens":5823,"usd":0.120235,"stage2_stop_reason":"end_turn"},"total_usd":0.26946,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"Crystal structures of human FKBP12 complexed with FK506 and rapamycin revealed a novel fold (five-stranded beta-sheet wrapping a short alpha-helix) with both ligands binding in a cavity defined by the beta-sheet, alpha-helix and three loops via hydrogen bonds and an unusual carbonyl binding pocket. The structures suggest how peptidyl-prolyl isomerase (PPIase) catalytic activity could operate.\",\n      \"method\": \"X-ray crystallography (high-resolution structures of FKBP12-FK506 and FKBP12-rapamycin complexes)\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — atomic-resolution crystal structures with functional validation of ligand-binding mode, foundational structural paper\",\n      \"pmids\": [\"7678431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"FKBP12 binds the mammalian TOR homolog RAFT1 (mTOR) in a rapamycin-dependent fashion; purified FKBP12-rapamycin complex specifically precipitates the 289-kDa RAFT1/mTOR protein, identifying it as the direct cellular target of the FKBP12-rapamycin complex.\",\n      \"method\": \"Affinity purification (FKBP12-rapamycin affinity matrix), peptide sequencing, cDNA cloning\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — replicated independently in multiple labs (PMID 7518356, 7822316, 7539137), biochemical pulldown with sequence confirmation\",\n      \"pmids\": [\"7518356\", \"7822316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"An 11-kDa FKBP12-rapamycin-binding (FRB) domain within FRAP/mTOR (residues 2025–2114) was identified as the minimal binding domain for the FKBP12-rapamycin complex. Mutagenesis at Ser2035 showed that most substitutions abolish binding, whereas Ser2035Ala retains binding, suggesting steric rather than phosphorylation-based regulation at this site.\",\n      \"method\": \"In vitro transcription/translation, proteolysis mapping, site-directed mutagenesis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with mutagenesis defining the minimal binding domain\",\n      \"pmids\": [\"7539137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Crystal structure of the ternary FKBP12–rapamycin–FRB(FRAP) complex at 2.7 Å revealed that rapamycin simultaneously occupies two different hydrophobic binding pockets on FKBP12 and FRB, mediating protein dimerization with extensive rapamycin-protein interactions but fewer direct protein-protein contacts.\",\n      \"method\": \"X-ray crystallography (2.7 Å resolution ternary complex)\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — atomic-resolution ternary complex structure, refined further at 2.2 Å (PMID 10089303)\",\n      \"pmids\": [\"8662507\", \"10089303\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Crystal structure of human FKBP12-FK506 bound to calcineurin (CaN) at 3.5 Å resolution revealed the FKBP12-FK506 complex displaces the calcineurin auto-inhibitory element from the active site. Surface residues Asp-37, Arg-42, and His-87 of FKBP12 (identified by mutagenesis) directly participate in calcineurin complex formation; R42K/H87V double mutant reduced calcineurin affinity ~600-fold without affecting PPIase activity or FK506 binding.\",\n      \"method\": \"X-ray crystallography, site-directed mutagenesis, calcineurin inhibition assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure combined with mutagenesis defining contact residues, two independent papers\",\n      \"pmids\": [\"8524402\", \"1379588\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"FKBP12 specifically interacts with type I receptors of the TGF-beta family (identified by yeast two-hybrid screen); deletion and point mutation studies confirmed specificity, and excess FK506 competed with type I receptors for FKBP12 binding, suggesting shared/overlapping binding sites.\",\n      \"method\": \"Yeast two-hybrid screen, co-immunoprecipitation, competition binding with FK506\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — replicated and extended by multiple independent labs (PMID 8756725, 9233797)\",\n      \"pmids\": [\"7518616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"FKBP12 acts as a common inhibitor of TGF-beta family type I receptors: it binds to ligand-free type I receptor and is released upon ligand-induced, type II receptor-mediated phosphorylation. Two FKBP12 point mutations (G89P, I90K) abolish its inhibitory activity; overexpression of myristylated FKBP12 specifically inhibits two TGF-beta-activated pathways.\",\n      \"method\": \"Co-immunoprecipitation, overexpression with point mutations, cell-based inhibition assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (Co-IP, mutagenesis, overexpression phenotype), replicated across labs\",\n      \"pmids\": [\"8756725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"FKBP12 binds TbetaR-I via the rapamycin/Leu-Pro binding pocket of FKBP12 and a Leu-Pro sequence adjacent to the activating phosphorylation sites of TbetaR-I. FKBP12 does not block TbetaR-I/TbetaR-II association but inhibits TbetaR-I phosphorylation by TbetaR-II; rapamycin reverses this inhibition by blocking FKBP12 binding to TbetaR-I.\",\n      \"method\": \"Mutagenesis of FKBP12 and TbetaR-I binding sites, kinase phosphorylation assays, rapamycin competition\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mechanistic dissection using mutagenesis at both binding partners plus in vitro kinase assays\",\n      \"pmids\": [\"9233797\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"FKBP12 binds the inositol 1,4,5-trisphosphate receptor (IP3R) at residues Leu1400-Pro1401 (a leucyl-prolyl dipeptide epitope resembling FK506) and this interaction enables FKBP12 to anchor calcineurin to the IP3R, presumably to modulate the receptor's phosphorylation status.\",\n      \"method\": \"Mutagenesis mapping, co-immunoprecipitation, peptide competition assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical mapping with mutagenesis, single lab but multiple methods\",\n      \"pmids\": [\"9346894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"FKBP12-deficient mice develop severe dilated cardiomyopathy, ventricular septal defects resembling noncompaction of left ventricular myocardium, and altered calcium release activity of both skeletal (RyR1) and cardiac (RyR2) ryanodine receptors; FKBP12 is dispensable for TGF-beta-mediated signaling in vivo.\",\n      \"method\": \"Conditional knockout mice (ES cell technology), physiological Ca2+ release measurements, cardiac phenotyping\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function with defined cardiac and ryanodine receptor phenotypes, replicated by other groups\",\n      \"pmids\": [\"9461216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"FKBP12 physically and stoichiometrically binds RyR1 in skeletal muscle (4 FKBP12 per tetrameric RyR1); dissociation of FKBP12 from the RyR complex by FK-590 or rapamycin increases RyR1 open probability and Ca2+ leak. PPIase-deficient FKBP12 mutants can bind and modulate RyR1 normally, indicating RyR1 modulation is independent of PPIase activity.\",\n      \"method\": \"Exchange binding assays, Ca2+ flux measurements, site-directed mutagenesis of FKBP12 PPIase active site\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro reconstitution with mutagenesis, functional flux assays, replicated across multiple labs\",\n      \"pmids\": [\"7531689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The cardiac ryanodine receptor (RyR2) selectively binds FKBP12.6 but not FKBP12 from the cardiac sarcoplasmic reticulum, whereas skeletal RyR1 binds both isoforms. This differential selectivity explains the isoform specificity of RyR-FKBP complexes in different muscle types.\",\n      \"method\": \"35S-labeled FKBP12 and FKBP12.6 binding assays on FKBP-stripped cardiac and skeletal SR vesicles\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct binding experiments with radiolabeled probes on native membranes, replicated\",\n      \"pmids\": [\"8702774\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Val2461 in RyR1 is a critical residue required for FKBP12 binding; substitution with Gly, Glu, or Ile prevents FKBP12 binding and results in RyR1 channels with increased gating frequency; normal channel function can be restored by adding FKBP12.6 to V2461I mutant channels.\",\n      \"method\": \"Site-directed mutagenesis of RyR1, single-channel electrophysiology, FKBP12 binding assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis with functional rescue and single-channel readout\",\n      \"pmids\": [\"11279144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"FKBP12 deficiency causes G1 cell cycle arrest via TGF-beta receptor over-signaling, leading to marked upregulation of p21(WAF1/CIP1) through the p38 MAP kinase pathway (not ERK or SMAD); dominant-negative TGF-beta receptor rescues the arrest.\",\n      \"method\": \"FKBP12-/- mouse cells, transfection rescue, dominant-negative TGF-beta receptor, p38 inhibitor, p21 western blotting\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function with multiple orthogonal epistasis experiments defining pathway\",\n      \"pmids\": [\"11226255\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"FKBP12-deficient mice exhibit exercise-induced cardiac arrhythmias; exercise-induced PKA phosphorylation of RyR2 partially dissociates FKBP12.6 from RyR2, increasing intracellular Ca2+ release; CPVT-associated RyR2 mutations reduce FKBP12.6 affinity and increase channel activity under exercise-simulating conditions.\",\n      \"method\": \"FKBP12.6 knockout mice, single-channel electrophysiology, in vivo exercise challenge, co-immunoprecipitation\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with in vivo cardiac phenotype and mechanistic biochemistry\",\n      \"pmids\": [\"12837242\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"PKA phosphorylation at Ser2808 of RyR2 does NOT dissociate FKBP12.6 from RyR2; FKBP12.6 binds both the phosphorylated and nonphosphorylated forms; the S2808D phosphomimetic mutant retains FKBP12.6 binding. Complete PKA phosphorylation at Ser2808 disrupts neither recombinant nor native FKBP12.6-RyR2 complex.\",\n      \"method\": \"Site-specific phospho-antibodies, co-immunoprecipitation with recombinant and native RyR2, exogenous PKA phosphorylation\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — negative result established with multiple rigorous methods and site-specific tools; contradicts earlier claims\",\n      \"pmids\": [\"14715536\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Cryo-EM difference mapping at 16 Å resolution determined the 3D position and unique orientation of FKBP12 bound to RyR1; the FK506-binding site of FKBP12 faces toward RyR1, explaining how FK506 causes FKBP12 dissociation; Gln3 of FKBP12 was identified as directly participating in the RyR1 interaction.\",\n      \"method\": \"Cryo-electron microscopy, single-particle image processing, atomic model fitting\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — cryo-EM structural determination with atomic model fitting, single lab\",\n      \"pmids\": [\"16405911\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"FKBP12 binding to RyR1 enhances the gain of skeletal muscle excitation-contraction (EC) coupling; RyR1 mutations disrupting FKBP12 binding (V2461G, V2461I) reduce voltage-gated Ca2+ release ~50%; co-expression of FKBP12.6 restores normal EC coupling in V2461I myotubes. FKBP12 binding does not affect retrograde coupling.\",\n      \"method\": \"Expression of RyR1 mutants in dyspedic myotubes (RyR1-KO), voltage-clamp fluorometry, caffeine-induced Ca2+ release\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — rescue experiment with mutagenesis in null background, multiple functional readouts\",\n      \"pmids\": [\"12704193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Brain-specific FKBP12 knockout mice show increased basal mTOR phosphorylation, enhanced mTOR-Raptor interactions, increased p70 S6K phosphorylation, enhanced LTP, and enhanced contextual fear memory with autistic/OCD-like perseveration; the LTP enhancement is rapamycin-resistant but anisomycin-sensitive, implicating altered translational control.\",\n      \"method\": \"Conditional knockout mice (brain-specific), co-immunoprecipitation of mTOR-Raptor, electrophysiology (LTP), behavioral assays\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with multiple orthogonal biochemical and functional readouts\",\n      \"pmids\": [\"19081378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Endothelial cell-specific (not cardiomyocyte-specific) ablation of Fkbp1a recapitulates ventricular hypertrabeculation and noncompaction; Fkbp1a is a negative modulator of activated Notch1 (N1ICD) in endocardial cells; N1ICD is upregulated upon Fkbp1a ablation and direct inhibition of Notch signaling reduces hypertrabeculation.\",\n      \"method\": \"Conditional knockout mice (endothelial vs cardiomyocyte-specific Cre), in vivo and in vitro Notch1 activity assays, N1ICD stability measurements\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific KO with epistasis (Notch inhibition rescue), multiple orthogonal methods\",\n      \"pmids\": [\"23571217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"FKBP12 acts as an adaptor for the Smad7-Smurf1 complex on the activin type I receptor (ALK4): after initial ligand-induced dissociation, FKBP12 re-associates with ALK4 and recruits Smad7. FK506, which dissociates FKBP12 from the receptor, decreases Smad7-Smurf1 interaction and inhibits Smurf1-mediated ubiquitination of the type I receptor.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, FK506 competition\",\n      \"journal\": \"Journal of molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and ubiquitination assays, single lab\",\n      \"pmids\": [\"16720724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FKBP12 preferentially binds the BMP type I receptor ALK2 and inhibits hepcidin expression; sequestration of FKBP12 by rapamycin or tacrolimus activates BMP-SMAD signaling and increases hepcidin both in vitro and in vivo; ALK2 mutants defective in FKBP12 binding show ligand-independent hepcidin activation and gain responsiveness to the non-canonical ligand Activin A.\",\n      \"method\": \"Pharmacologic (rapamycin/tacrolimus treatment), genetic (ALK2 binding-deficient mutants), in vitro and murine hepatocyte models, SMAD signaling assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal approaches (pharmacologic + genetic) with in vivo validation\",\n      \"pmids\": [\"28864813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FKBP12 endogenously regulates calcineurin activity toward a specific subset of substrates and promotes dephosphorylation of proteins contributing to alpha-synuclein toxicity; partial pharmacological disruption of FKBP12-calcineurin interaction with low-dose tacrolimus protects against alpha-synuclein pathology in a rat PD model.\",\n      \"method\": \"Quantitative phosphoproteomics, genetic manipulation of FKBP12-calcineurin interaction, in vivo rat PD model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — quantitative phosphoproteomics with in vivo validation, multiple orthogonal methods\",\n      \"pmids\": [\"29229832\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FKBP12 is essential for necroptosis: it is required for RIPK1 and RIPK3 expression and spontaneous phosphorylation, necrosome formation, and RIPK1-RIPK3-MLKL signaling pathway activation in response to TNF receptor 1 ligation; FKBP12 may target RIPK1 and RIPK3 directly.\",\n      \"method\": \"siRNA/shRNA knockdown, in vitro and in vivo TNF-induced necroptosis assays, western blot for necrosome components\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined molecular phenotype, single lab, mechanistic details incompletely resolved from abstract\",\n      \"pmids\": [\"31028177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FKBP12 interacts with MDM2 and induces MDM2 degradation via disruption of the MDM2/MDM4 interaction and induction of MDM2 self-ubiquitination; FKBP12 preferentially degrades cytoplasmic MDM2; DNA-damage-induced nuclear MDM2 translocates to the cytoplasm where it is targeted by FKBP12, leading to constitutive p53 activation and sensitization of cancer cells to apoptosis.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, subcellular fractionation, siRNA knockdown, apoptosis assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ubiquitination assay plus functional apoptosis readout, single lab\",\n      \"pmids\": [\"27617579\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"FKBP12 is the only FKBP family member required for FK506-mediated T-cell growth inhibition; FK506-induced T-cell suppression is abolished in FKBP12-deficient cells but not FKBP12.6-deficient cells.\",\n      \"method\": \"FKBP12-/- and FKBP12.6-/- mouse T cells, T-cell growth inhibition assay with FK506\",\n      \"journal\": \"Transplantation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct genetic comparison of isoform-specific KO cells with functional readout\",\n      \"pmids\": [\"12085010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"FKBP12 (not FKBP12.6) is a high-affinity activator of cardiac RyR2, sensitizing the channel to cytosolic Ca2+; FKBP12.6 has very low efficacy on RyR2 but antagonizes FKBP12 effects. Physiological concentrations of FKBP12 (3 µM) increase Ca2+ wave frequency and decrease SR Ca2+ content in cardiac cells.\",\n      \"method\": \"Single-channel bilayer electrophysiology, Ca2+ wave imaging in permeabilized cardiac cells, mathematical modeling\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — single-channel recordings with physiological concentrations plus cell imaging, single lab\",\n      \"pmids\": [\"22363773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"FKBP12 inhibits EGF-induced EGFR autophosphorylation at all internal phosphorylation sites by targeting the EGFR kinase domain; altering intracellular FKBP12 levels changes EGFR autophosphorylation level.\",\n      \"method\": \"In vitro kinase assays, siRNA knockdown/overexpression with EGFR phosphorylation readout\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro kinase inhibition plus cellular gain/loss-of-function, single lab\",\n      \"pmids\": [\"22103444\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"RyR1 S-nitrosylation (but not S-glutathionylation) specifically increases the Kd of FKBP12 binding to RyR1 by four- to five-fold, reducing FKBP12 association with the channel.\",\n      \"method\": \"Radiolabeled [35S]FKBP12 binding assays, redox modification of native RyR1 in triads\",\n      \"journal\": \"Antioxidants & redox signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding assay with specific redox modifications, single lab\",\n      \"pmids\": [\"15998242\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystal structures of RyR SPRY1 domain at 1.2–1.5 Å combined with FRET studies and molecular dynamics/mutagenesis identified a hydrophobic cluster within SPRY1 as crucial for FKBP binding; the RyR1 disease mutation N760D disrupts FKBP binding by interfering with SPRY1 folding.\",\n      \"method\": \"X-ray crystallography, FRET, cryo-EM docking, site-directed mutagenesis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures combined with mutagenesis and FRET, multiple orthogonal methods\",\n      \"pmids\": [\"26245150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Cryo-EM structure of RyR2-FKBP12.6 complex at 11.8 Å revealed that FKBP12.6 binding rigidifies the HD2 (helical domain 2/Clamp) domain of RyR2, stabilizing the closed state; two RyR2 conformations were identified corresponding to different phosphorylation states of the P2 domain, suggesting phosphorylation lowers the energy barrier to channel opening.\",\n      \"method\": \"Cryo-electron microscopy (11.8 Å resolution), atomic model building\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — cryo-EM structure with atomic modeling, single lab\",\n      \"pmids\": [\"28536302\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FKBP12 is expressed along the actin cytoskeleton of podocytes and associates with filamentous actin (F-actin), 14-3-3, and synaptopodin; FKBP12 silencing reduces 14-3-3 expression, F-actin staining, and process formation; tacrolimus restores FKBP12 at F-actin and enhances FKBP12-synaptopodin interaction, ameliorating podocyte injury.\",\n      \"method\": \"RNA silencing, confocal immunofluorescence, co-immunoprecipitation, podocyte morphology assays\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function plus protein interaction studies with functional readout, single lab\",\n      \"pmids\": [\"34662453\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FKBP12 over-expression suppresses basal BMP signaling of thirteen of fourteen FOP/DIPG-associated gain-of-function ALK2 mutants; the PF197-8L (L197) mutant uniquely resists FKBP12 suppression because modeled steric clash between ALK2-L197 and FKBP12-D36 disrupts binding; co-expression of BMP type II receptors or ligand stimulation relieves FKBP12 suppression by disrupting the mutant ALK2–FKBP12 interaction.\",\n      \"method\": \"Overexpression studies, signaling assays (BMP-SMAD), molecular modeling of binding interface\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic mutagenesis panel with functional signaling readout, supported by structural modeling, single lab\",\n      \"pmids\": [\"29551750\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Fully synthetic FKBP12-mTOR molecular glues were discovered from a FKBP-focused ligand library; crystal structure of the ternary complex revealed the compounds target a similar FRB domain surface as rapamycin but with a radically different interaction pattern; structure-guided optimization yielded compounds inducing FKBP12-FRB complex formation in cells.\",\n      \"method\": \"Biochemical screening, X-ray crystallography of ternary complex, structure-activity relationship optimization, cell-based FKBP12-FRB dimerization assay\",\n      \"journal\": \"Chemical science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure of ternary complex plus cell-based validation, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"39916884\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"TOR1 and mTOR (as well as TOR2) directly interact with FKBP12-rapamycin complex; a conserved serine residue (Ser1972 in TOR1, corresponding to Ser2035 in mTOR) is required for this interaction; mutations at this serine confer rapamycin resistance by preventing FKBP12-rapamycin binding; FKBP12 prolyl isomerase activity is not required for TOR binding.\",\n      \"method\": \"Yeast two-hybrid (rapamycin-dependent), site-directed mutagenesis, rapamycin-resistance assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two-hybrid plus mutagenesis plus in vivo resistance phenotype, replicated across multiple labs\",\n      \"pmids\": [\"7499212\", \"7528205\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"FKBP12 undergoes upregulation during nerve regeneration (not degeneration) with a time course paralleling GAP-43 mRNA; FKBP12 is rapidly axonally transported at rates similar to GAP-43 following sciatic nerve crush.\",\n      \"method\": \"In situ hybridization, nerve crush models, axonal transport measurements\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — localization and expression correlating with regeneration-specific context, direct transport measurements\",\n      \"pmids\": [\"7536825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Immunophilins CyclophilinA and FKBP12 interact with transcription factor YY1 in yeast two-hybrid and in mammalian cells; cyclosporin A and FK506 disrupt these interactions respectively; overexpression of FKBP12 alters YY1-regulated transcription in a promoter-dependent manner.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation in mammalian cells, transcription reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two-hybrid validated by Co-IP in mammalian cells with functional transcriptional readout, single lab\",\n      \"pmids\": [\"7541038\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"FKBP12 modulates the binding of RyR1 to the II-III loop of the dihydropyridine receptor (DHPR): FKBP12 potentiates RyR1 binding to the Thr671-Leu690 domain of DHPR alpha1-subunit with EC50 of 10 nM, and this potentiation is inhibited by rapamycin or FK506. Removal of FKBP12 from RyR1 abolishes the DHPR domain A-induced increase in RyR1 open probability.\",\n      \"method\": \"Surface plasmon resonance, polystyrene bead binding assays, single-channel lipid bilayer electrophysiology\",\n      \"journal\": \"Biophysical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding measurement plus functional channel assay, single lab\",\n      \"pmids\": [\"11751303\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FKBP1A (FKBP12) is a cytoplasmic cis-trans peptidyl-prolyl isomerase that functions as a molecular scaffold: it binds FK506 and rapamycin with high affinity (defined by atomic crystal structures), forming ternary complexes that inhibit calcineurin (with FK506) or recruit and inhibit mTOR/FRAP (with rapamycin); it constitutively binds and stabilizes the skeletal muscle ryanodine receptor (RyR1) at Val2461 in a PPIase-independent manner to suppress aberrant Ca2+ release and enhance EC coupling gain; it serves as a gatekeeper of TGF-beta family type I receptors (including ALK2, ALK4, TbetaR-I) by occupying their GS-domain Leu-Pro motif to prevent ligand-independent signaling; it anchors calcineurin to the IP3R; it endogenously regulates calcineurin's phosphoproteome; it suppresses EGFR autophosphorylation; it promotes MDM2 self-ubiquitination to activate p53; it mediates necroptotic RIPK1-RIPK3-MLKL signaling; and in endocardial cells it negatively regulates Notch1 stability to control ventricular trabeculation, with loss of FKBP12 causing dilated cardiomyopathy and hypertrabeculation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FKBP1A (FKBP12) is a small cytoplasmic peptidyl-prolyl isomerase whose dominant biological role is as a high-affinity ligand-binding scaffold and a constitutive regulator of membrane receptor and channel complexes [#0, #5]. Its defining pharmacological property is binding the immunosuppressant FK506 and the macrolide rapamycin within a cavity formed by its five-stranded beta-sheet, alpha-helix and three loops [#0]; the resulting drug-bound complexes act as composite surfaces that engage second targets. The FKBP12-FK506 complex docks onto calcineurin, displacing its autoinhibitory element through surface residues Asp37, Arg42 and His87 to block phosphatase activity independently of PPIase function [#4], and FKBP12 is the unique family member required for FK506-mediated T-cell suppression [#25]. The FKBP12-rapamycin complex instead binds the FRB domain of mTOR/FRAP at a serine-gated pocket (Ser2035), with rapamycin bridging two hydrophobic surfaces to dimerize the proteins [#1, #3, #34]; loss of FKBP12 in brain derepresses mTOR-Raptor signaling and S6K phosphorylation [#18]. Independently of drugs, FKBP12 occupies a Leu-Pro motif adjacent to the activating phosphorylation sites of TGF-beta family type I receptors, holding ligand-free receptors silent until type II receptor-mediated phosphorylation releases it [#6, #7]; this gatekeeper role extends to BMP receptor ALK2, where FKBP12 suppresses ligand-independent and gain-of-function signaling that drives hepcidin expression and FOP-associated mutations [#21, #32], and to ALK4, where re-association recruits the Smad7-Smurf1 ubiquitination machinery [#20]. FKBP12 also constitutively and stoichiometrically binds the ryanodine receptors via a hydrophobic cluster in the SPRY1 domain and the critical RyR1 residue Val2461, stabilizing the closed channel state and tuning Ca2+ release and excitation-contraction coupling gain in a PPIase-independent manner [#10, #12, #17, #29, #30]. Genetic ablation reveals physiological consequences across tissues: global loss causes dilated cardiomyopathy with hypertrabeculation/noncompaction and disordered ryanodine receptor Ca2+ release [#9], and endocardial-specific loss recapitulates this phenotype by stabilizing activated Notch1 [#19]. Additional regulatory targets include the IP3R, to which FKBP12 anchors calcineurin [#8], the EGFR kinase domain whose autophosphorylation it suppresses [#27], MDM2 self-ubiquitination promoting p53 activation [#24], and the RIPK1-RIPK3-MLKL necroptotic pathway [#23].\"\n  ,\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Establishing the atomic architecture of FKBP12 and how it captures FK506 and rapamycin defined the structural basis for all of its drug-mediated functions.\",\n      \"evidence\": \"High-resolution X-ray crystallography of FKBP12-FK506 and FKBP12-rapamycin complexes\",\n      \"pmids\": [\"7678431\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure alone did not establish the cellular target of either drug complex\", \"PPIase catalytic mechanism inferred but not functionally dissected\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Identifying that FKBP12 binds type I TGF-beta receptors and, separately, the mTOR target revealed that FKBP12 has both drug-dependent and drug-independent receptor partners.\",\n      \"evidence\": \"Yeast two-hybrid plus Co-IP for TGF-beta receptors; FKBP12-rapamycin affinity purification of RAFT1/mTOR\",\n      \"pmids\": [\"7518616\", \"7518356\", \"7822316\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of receptor binding not yet defined\", \"Binding sites on receptors unmapped\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Mapping the FRB domain and the Ser2035 gating residue on mTOR, and the calcineurin contact residues on FKBP12, defined how the ternary drug complexes select and inhibit their targets.\",\n      \"evidence\": \"Proteolysis mapping/mutagenesis of mTOR FRB; crystallography plus mutagenesis of FKBP12-FK506-calcineurin; rapamycin-resistance two-hybrid\",\n      \"pmids\": [\"7539137\", \"8524402\", \"1379588\", \"7499212\", \"7528205\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PPIase activity contributes to target engagement (later shown dispensable)\", \"In vivo selectivity of calcineurin inhibition not yet measured\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Demonstrating stoichiometric FKBP12 binding to RyR1 and PPIase-independent channel modulation established FKBP12 as a constitutive structural regulator of Ca2+ release channels.\",\n      \"evidence\": \"Exchange binding assays, Ca2+ flux measurements, PPIase-dead mutagenesis on skeletal muscle RyR1\",\n      \"pmids\": [\"7531689\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise RyR1 binding epitope not yet identified\", \"Physiological role of channel stabilization untested in vivo\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Defining FKBP12 as a phosphorylation-released gatekeeper of TGF-beta type I receptors and resolving the FKBP12-rapamycin-FRB ternary structure clarified the mechanistic logic of both its receptor-silencing and drug-bridging functions.\",\n      \"evidence\": \"Co-IP, FKBP12 point mutants, myristylated overexpression assays; 2.7 A ternary complex crystallography\",\n      \"pmids\": [\"8756725\", \"8662507\", \"10089303\", \"8702774\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generalization across all type I receptors initially incomplete\", \"RyR isoform selectivity mechanism unresolved\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Pinpointing the Leu-Pro receptor motif engaged by the FKBP12 rapamycin pocket explained how it inhibits type I receptor phosphorylation and how rapamycin reverses this, and extended the anchoring role to the IP3R-calcineurin axis.\",\n      \"evidence\": \"Reciprocal mutagenesis of FKBP12 and TbetaR-I with kinase assays; mutagenesis/Co-IP mapping on IP3R\",\n      \"pmids\": [\"9233797\", \"9346894\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"IP3R-calcineurin functional output (Co-IP-based, single lab) not quantified\", \"Receptor occupancy dynamics in vivo unclear\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Genetic ablation showed FKBP12 is physiologically essential for cardiac development and ryanodine receptor regulation while being dispensable for TGF-beta signaling in vivo, separating its developmental and pharmacological roles.\",\n      \"evidence\": \"Conditional knockout mice with cardiac phenotyping and Ca2+ release measurements\",\n      \"pmids\": [\"9461216\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell type driving cardiomyopathy not yet localized\", \"Molecular link between FKBP12 loss and the developmental defect undefined\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identifying RyR1 Val2461 as the binding-critical residue and showing FKBP12 loss derepresses TGF-beta receptor signaling toward p21/p38-driven G1 arrest linked structural binding determinants to discrete physiological outputs.\",\n      \"evidence\": \"RyR1 site-directed mutagenesis with single-channel electrophysiology; FKBP12-/- cells with dominant-negative receptor and p38 epistasis\",\n      \"pmids\": [\"11279144\", \"11226255\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Val2461 substitution alters gating mechanistically not fully resolved\", \"Selectivity of p38 versus SMAD branch downstream of receptor over-signaling\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Functional studies established that FKBP12 binding sets skeletal EC coupling gain and that FKBP12.6 dissociation underlies exercise-induced cardiac arrhythmia, connecting channel occupancy to muscle physiology.\",\n      \"evidence\": \"RyR1 mutant rescue in dyspedic myotubes with voltage-clamp fluorometry; FKBP12.6 knockout mice with exercise challenge and single-channel recordings\",\n      \"pmids\": [\"12704193\", \"12837242\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PKA phosphorylation truly dissociates FKBP12.6 was later contested\", \"Quantitative contribution of FKBP12 to in vivo EC coupling gain\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"A rigorous negative result showed PKA phosphorylation at RyR2 Ser2808 does not dissociate FKBP12.6, refining the model of how phosphorylation and FKBP occupancy interact.\",\n      \"evidence\": \"Phospho-specific antibodies and Co-IP with recombinant and native RyR2, phosphomimetic mutant\",\n      \"pmids\": [\"14715536\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reconciliation with earlier dissociation claims unresolved\", \"Alternative regulators of FKBP12.6-RyR2 affinity not defined here\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Brain-specific deletion demonstrated FKBP12 restrains mTOR-Raptor signaling and translation-dependent synaptic plasticity and behavior in vivo, generalizing its negative-regulator role beyond drug-bound contexts.\",\n      \"evidence\": \"Conditional brain knockout with mTOR-Raptor Co-IP, LTP electrophysiology and behavioral assays\",\n      \"pmids\": [\"19081378\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biochemical mechanism of mTOR inhibition by endogenous FKBP12 undefined\", \"Rapamycin-resistant LTP component not mechanistically resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Cell-type-specific ablation localized the cardiomyopathy to endocardium and identified Notch1 stabilization as the causal mechanism, resolving the long-standing developmental phenotype.\",\n      \"evidence\": \"Endothelial- versus cardiomyocyte-specific Cre knockout with N1ICD stability assays and Notch inhibition rescue\",\n      \"pmids\": [\"23571217\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct physical mechanism by which FKBP12 destabilizes N1ICD not shown\", \"Whether PPIase activity is involved unaddressed\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"High-resolution structural work on the RyR SPRY1 domain and cryo-EM of the RyR2-FKBP12.6 complex defined the binding interface and the conformational mechanism of channel stabilization.\",\n      \"evidence\": \"SPRY1 crystallography with FRET and mutagenesis; cryo-EM of RyR2-FKBP12.6 with atomic modeling\",\n      \"pmids\": [\"26245150\", \"28536302\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Resolution insufficient to model side-chain contacts at the interface\", \"Link between FKBP occupancy and the P2-domain phosphorylation conformations inferred from structure\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Expanding FKBP12 to BMP receptor ALK2/hepcidin control and to endogenous calcineurin substrate selectivity broadened its gatekeeper and phosphatase-targeting roles into iron homeostasis and neurodegeneration.\",\n      \"evidence\": \"Pharmacologic and genetic ALK2 binding-deficient mutants with SMAD/hepcidin assays; quantitative phosphoproteomics with a rat PD model\",\n      \"pmids\": [\"28864813\", \"29229832\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether calcineurin substrate selectivity is direct or via anchoring not fully resolved\", \"Therapeutic window of FKBP12-calcineurin disruption undefined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Loss-of-function studies placed FKBP12 within necroptotic RIPK1-RIPK3-MLKL signaling, adding a programmed cell death role to its repertoire.\",\n      \"evidence\": \"siRNA/shRNA knockdown with TNF-induced necroptosis assays and necrosome western blots\",\n      \"pmids\": [\"31028177\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether FKBP12 directly binds RIPK1/RIPK3 not demonstrated\", \"Single lab; mechanism of necrosome regulation incompletely resolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Discovery of fully synthetic FKBP12-mTOR molecular glues showed the FKBP12-FRB interface can be re-engineered with non-rapamycin chemotypes, extending its scaffold function to designed proximity inducers.\",\n      \"evidence\": \"Biochemical screening, ternary complex crystallography and cell-based FKBP12-FRB dimerization assays\",\n      \"pmids\": [\"39916884\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream functional consequences of synthetic dimerization in vivo untested\", \"Selectivity across FKBP family not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How FKBP12 mechanistically distinguishes and switches among its many partners (receptors, channels, phosphatases, ubiquitin ligases, death-signaling kinases) within a single cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model for partner selection or competition\", \"Role of PPIase activity in most non-channel functions undefined\", \"Direct structural mechanism of Notch1, MDM2 and necrosome regulation lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016853\", \"supporting_discovery_ids\": [0, 10]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [6, 7, 21]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 6, 10, 27]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [8, 20]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [31]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [5, 6, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 6, 7, 21, 18]},\n      {\"term_id\": \"R-HSA-397014\", \"supporting_discovery_ids\": [10, 17, 12]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [9, 19]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 25]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [23, 24]}\n    ],\n    \"complexes\": [\n      \"FKBP12-rapamycin-mTOR/FRB ternary complex\",\n      \"FKBP12-FK506-calcineurin complex\",\n      \"RyR1/RyR2-FKBP12 channel complex\",\n      \"Smad7-Smurf1-ALK4 complex\"\n    ],\n    \"partners\": [\n      \"MTOR\",\n      \"PPP3CA\",\n      \"RYR1\",\n      \"RYR2\",\n      \"TGFBR1\",\n      \"ACVR1\",\n      \"ITPR1\",\n      \"EGFR\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}